NEWS&EVENTS

BACK TO LIST
May 05th 2020 The EF Clif leads the REP COVID Study This is a Phase II Clinical Trial aimed at assessing the impact of plasma exchange with 5% albumin in patients with COVID-19 disease and invasive mechanical ventilation

The trial is endorsed by the EF Clif and has engaged four hospitals in the area of Barcelona: Hospital Clinic, Hospital de Bellvitge, Hospital del Mar and Hospital Germans Trias i Pujol.

The REP COVID study is led by two investigators of the EF Clif, Dr Javier Fernández in the clinical setting and Dr Joan Clària in the management of biological samples. Grifols is supporting the clinical study by supplying the investigational products: 5% albumin and intravenous immunoglobulin. The EF Clif data management center has designed the eCRF and will perform the data analysis.

BACK TO LIST